Alllex/E+ via Getty Images Tech bull Tom Lee says he sees another sign of a bottom in software stocks. The head of research at Fundstrat highlighted a post on X about the recent volume spike in the iShares Expanded Tech-Software Sector ETF ( IGV ), which is down 25% year to date. The post by CyclesFan noted that on Feb. 4 IGV had the biggest volume in history, while it had the second-biggest volum...
Alllex/E+ via Getty Images Tech bull Tom Lee says he sees another sign of a bottom in software stocks. The head of research at Fundstrat highlighted a post on X about the recent volume spike in the iShares Expanded Tech-Software Sector ETF ( IGV ), which is down 25% year to date. The post by CyclesFan noted that on Feb. 4 IGV had the biggest volume in history, while it had the second-biggest volume on Feb. 5. On Feb. 23 it had the third-biggest volume in history, and on Feb. 24 it had the fourth-biggest, adding these "are clear signs of capitulation." Lee called that "another sign of a bottom." IGV's top-five holdings are Microsoft ( MSFT ), Palantir ( PLTR ), Oracle ( ORCL ), Salesforce ( CRM ) and Intuit ( INTU ). CyclesFan More on iShares Expanded Tech-Software Sector ETF 'SaaSpocalypse' Survival Guide There's Truth In SaaSpocalypse: Forward Deployed Engineers Make IGV A Buy AI Vs. Software: The $2 Trillion Paradox Tech’s internal split: Semiconductor strength masks software breakdown There are selective opportunities within the software sell-off – analyst
Andrei Akushevich/iStock via Getty Images The dollar was initially sold during President Trump’s State of the Union Address. However, against most of the G10 currencies, it remains within the well-worn ranges, which may be reinforced by a busy option expiration schedule, which we discuss below. There are two notable exceptions. First is the Japanese yen, which sent to more than two-week lows follo...
Andrei Akushevich/iStock via Getty Images The dollar was initially sold during President Trump’s State of the Union Address. However, against most of the G10 currencies, it remains within the well-worn ranges, which may be reinforced by a busy option expiration schedule, which we discuss below. There are two notable exceptions. First is the Japanese yen, which sent to more than two-week lows following news of two dovish appointments to the BOJ board to replace members whose terms are ending. This reinforces the sense of Prime Minister Takaichi's monetary policy desires. Japanese stocks rallied, but JGBs sold off. Second, Australia’s January CPI was firmer than expected, and this pushed expectations a bit higher for another hike as soon as the May central bank meeting. The Australian dollar is the strongest of the G10 currencies today. Geopolitical tensions continue to run high. President Trump threatened Iran in his speech. Also, China warned that new investigations could end the US-Chinese tariff truce. Gold and oil are firmer. Prices G10 • The euro traded quietly between about $1.1765 and $1.1795 yesterday. Since last Friday’s tariff ruling, it has been in a roughly $1.1745-$1.1835 range. It remains in that range today. It rose slightly above $1.18 early today, during President Trump’s speech, but has come back off. There are options for nearly 3 bln euros struck there that expire today. • After reaching almost JPY156.30, a two-week high, in the local session yesterday, the greenback spent the North American session in a narrow range mostly between about JPY155.60 and JPY156.20, and a tight JPY155.60-JPY155.85 range after Europe closed. News that Prime Minister Takaichi nominated two doves to the central bank’s board to replace outgoing members (end of March and end of June) weighed on the yen, which is falling for the fifth session in past six. The dollar rose to almost JPY156.80, arguably helped by option-related demand, as about $2.85 bln in options at JPY156 e...
Diageo Shares Plunge Most In Two Years On Weaker Guidance, Dividend Cut Shares of Diageo Plc fell the most in 2 years after the maker of Guinness beer and Johnnie Walker whiskey cut its guidance for the second time this fiscal year amid soft demand in the US and China markets. The move marks an early challenge for new CEO Dave Lewis. The British distiller now expects organic net sales to decline b...
Diageo Shares Plunge Most In Two Years On Weaker Guidance, Dividend Cut Shares of Diageo Plc fell the most in 2 years after the maker of Guinness beer and Johnnie Walker whiskey cut its guidance for the second time this fiscal year amid soft demand in the US and China markets. The move marks an early challenge for new CEO Dave Lewis. The British distiller now expects organic net sales to decline by 2% to 3% this fiscal year, down from previous guidance of flat to slightly down, and said it would reduce its dividend. First-half results were mixed. Organic net sales fell 2.8%, worse than expected, while North America's operating profit plunged 15%, missing analyst estimates tracked by Bloomberg Consensus. Europe was a bright spot, with operating profit rising 10% and beating forecasts. Adjusted EPS slightly beat, but overall sales and operating profit were much softer than anticipated by analysts. Citi analyst Simon Hales said the cut to full-year organic sales growth guidance reflects a much weaker US environment and noted that it could prompt cuts to the 2027 outlook. He added that the dividend cut has "taken the shine off" what could otherwise have been seen as the "clearing event" for the stock to rally. At Goldman, analyst Natasha de la Grense said the big story in the earnings report is the dividend cut. She noted investors are still waiting for a proper turnaround plan from the new CEO: Main focus today is the dividend cut which is perhaps not a huge surprise (Mr Lewis did this when he arrived at Tesco) and arguably necessary but never welcome news on the day. They are targeting a 30-50% payout going forward with a minimum floor of 50c per annum (consensus FY26 100c). In terms of the H1, it's a miss on org sales (-2.8% vs cons -2%) driven by volumes (-0.9% vs cons -0.2%) which were particularly weak in North America (-4%). US spirits net sales fell -9.3%. Reported EBIT is more in line at $3,256m (consensus $3,213m) and org EBIT better (-2.8% vs cons -3.9%) driv...
CatLane 15 states, mostly led by Democrats, are suing the Trump administration, seeking judicial intervention to reverse recent changes the Centers for Disease Control and Prevention (CDC) introduced to the U.S. childhood vaccine schedule. The California and Arizona attorneys general announced that 14 states and Pennsylvania Governor Josh Shapiro teamed up to file the lawsuit on Tuesday, which cha...
CatLane 15 states, mostly led by Democrats, are suing the Trump administration, seeking judicial intervention to reverse recent changes the Centers for Disease Control and Prevention (CDC) introduced to the U.S. childhood vaccine schedule. The California and Arizona attorneys general announced that 14 states and Pennsylvania Governor Josh Shapiro teamed up to file the lawsuit on Tuesday, which challenges the CDC’s move to recommend fewer shots for most American children earlier this year. “Undermining confidence in vaccines will lead to lower vaccination rates and more infectious disease,” California Attorney General Rob Bonta said in a statement. “It will also drive up costs for states, including increased Medicaid spending and new expenses to combat misinformation and revise public health guidance.” In addition to the California and Arizona attorneys general, plaintiffs in the suit include AGs in Colorado, Connecticut, Delaware, Maine, Maryland, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, and Wisconsin, as well as the governor of Pennsylvania. The lawsuit filed in a Northern California federal court named the U.S. Department of Health and Human Services and Health Secretary Robert F. Kennedy Jr. as defendants. It also named the CDC and its acting director, Dr. Jay Bhattacharya. The lawsuit also challenges RFK Jr.'s decision to dismiss all members of the CDC’s Advisory Committee on Immunization Practices (ACIP) last year and replace them with his handpicked experts, some of whom have a history of criticizing messenger RNA-based COVID-19 shots. The case is similar to another lawsuit filed by some of the leading medical groups, including the American Academy of Pediatrics and the American Public Health Association, against the Trump administration in a federal court in Massachusetts earlier this month. Dear readers, we recognize that politics often intersect with the financial news of the day, so we invite you to click here to join the separate...
M. Suhail/iStock Editorial via Getty Images Dine Brands Global ( DIN ) fell in early trading on Wednesday after reporting Q4 revenue short of the consensus estimate of analysts. Revenue was up 6.3% year over year to $217.6M vs. $225.7M consensus. The revenue increase in Q4 was primarily driven by higher company-owned restaurant sales, mainly attributable to the increase in the number and timing of...
M. Suhail/iStock Editorial via Getty Images Dine Brands Global ( DIN ) fell in early trading on Wednesday after reporting Q4 revenue short of the consensus estimate of analysts. Revenue was up 6.3% year over year to $217.6M vs. $225.7M consensus. The revenue increase in Q4 was primarily driven by higher company-owned restaurant sales, mainly attributable to the increase in the number and timing of when the company acquired Applebee’s and IHOP restaurants from franchisees, offset by a decrease in franchise revenue due to a decrease in the number of franchise restaurants after the acquisition of franchised Applebee’s and IHOP restaurants. Applebee's year-over-year comparable domestic same-restaurant sales decreased 0.4% in Q4, while IHOP's domestic comparable same-restaurant sales increased 0.3%. Earnings per share of $1.46 topped the consensus mark of $1.06. Looking ahead, the restaurant company sees Applebee’s domestic system-wide comparable same-restaurant sales performance to range between 0% and 2%, and IHOP’s domestic system-wide comparable same-restaurant sales performance to range between 0% and 2%. Consolidated adjusted EBITDA is expected to range between approximately $220M and $230M. "Our 2026 guidance reflects continued targeted investments in growth initiatives that are supported by improving trends across both our franchise business and our company-owned portfolio, and we will continue to focus on efficiently deploying capital towards projects with high return on investment," highlighted CFO Vance Chang. Shares of Dine Brands Global ( DIN ) were down 2.1% in premarket trading. More on Dine Brands Global Dine Brands: The Dual-Branded Catalyst Is Real, But Timing Now Matters (Rating Downgrade) Dine Brands Global, Inc. (DIN) Presents at KeyBanc Capital Markets Consumer Conference 2025 Transcript Dine Brands Global, Inc. (DIN) Presents at Barclays 11th Annual Eat, Sleep, Play, Shop Conference 2025 Transcript Dine Brands Global Q4 2025 Earnings Preview Seekin...
piranka/E+ via Getty Images Overview Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025. Data by YCharts The company markets ANKTIVA (with BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer [NMIBC] with carcinoma in situ [CIS] with or without papillary tumors. While ANKTIVA has struggled out the gate—mainly due to BCG...
piranka/E+ via Getty Images Overview Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025. Data by YCharts The company markets ANKTIVA (with BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer [NMIBC] with carcinoma in situ [CIS] with or without papillary tumors. While ANKTIVA has struggled out the gate—mainly due to BCG shortages—I have always acknowledged its blockbuster potential in this indication. The problem for me has been ImmunityBio’s high cash burn—related to testing ANKTIVA in all kinds of indications outside of bladder cancer—and its valuation that seemed to already account for ANKTIVA in BCG-unresponsive NMIBC. The company’s recent rally—which began in January—has been sparked by a flurry of headlines. The article that follows takes another look at ANKTIVA in its currently FDA-approved indication—to establish a “floor” in ImmunityBio’s valuation—and evaluates whether or not recent developments support the company’s sky-high ~$10 billion enterprise value. Recent Developments ImmunityBio’s rally appears to have begun after reporting Phase 2b/3 NSCLC data on January 13. The press release features a few different data points from two different trials. The most touted data point was that “responders” (those with higher lymphocyte counts) lived longer than “non-responders.” In my opinion, this is kind of “stating the obvious.” This doesn’t necessarily prove that ANKTIVA caused them to live longer. It just supports that patients who are already healthier—or have more robust immune systems—respond better to treatment and naturally live longer regardless of the drug. ImmunityBio also emphasized Absolute Lymphocyte Count—or ALC—as a “key biological endpoint.” But this is not a survival metric like OS or PFS. And stimulating ALC alone is not guaranteed to translate into statistically significant survival improvements. When the company does cite OS, it is against “historical standard of c...
Tommy Schaefer released early from 18-year sentence for 2014 murder of Sheila von Wiese-Mack during luxury holiday Indonesia has freed and deported a US man after he spent 11 years in prison for the premeditated murder of his then girlfriend’s mother on the tourist island of Bali. Tommy Schaefer was sentenced to 18 years in prison for the 2014 murder of Sheila von Wiese-Mack, the mother of Heather...
Tommy Schaefer released early from 18-year sentence for 2014 murder of Sheila von Wiese-Mack during luxury holiday Indonesia has freed and deported a US man after he spent 11 years in prison for the premeditated murder of his then girlfriend’s mother on the tourist island of Bali. Tommy Schaefer was sentenced to 18 years in prison for the 2014 murder of Sheila von Wiese-Mack, the mother of Heather Mack, during a luxury holiday in a case that became known as the Bali suitcase murder. Continue reading...
Acadia Healthcare press release ( ACHC ): Q4 Non-GAAP EPS of $0.07 beats by $0.06 . Revenue of $821.5M (+6.1% Y/Y) beats by $21.37M . Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3%. Adjusted EBITDA was $99.8 million, compared with $153.1 million in the prior-year period ...
Acadia Healthcare press release ( ACHC ): Q4 Non-GAAP EPS of $0.07 beats by $0.06 . Revenue of $821.5M (+6.1% Y/Y) beats by $21.37M . Same facility revenue increased 4.4% compared with the fourth quarter of 2024, including an increase in patient days of 3.1% and an increase in revenue per patient day of 1.3%. Adjusted EBITDA was $99.8 million, compared with $153.1 million in the prior-year period and at the upper end of the Company’s implied fourth-quarter guidance range. Added 181 newly licensed beds during the fourth quarter, including 37 beds to existing facilities and 144 beds from new facilities opened in the fourth quarter. Full Year 2026 Financial Guidance Revenue of $3.37 to $3.45 billion Adjusted EBITDA of $575 to $610 million Adjusted earnings per diluted share of $1.30 to $1.55 (FY EPS consensus is $1.71; FY Revenue consensus is $3.40B). More on Acadia Healthcare The Bottom Fishing Club - Acadia Healthcare: Huge Short Squeeze Potential, Reversing Momentum Acadia Healthcare Company, Inc. (ACHC) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Acadia Healthcare Company, Inc. (ACHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Acadia Healthcare Q4 2025 Earnings Preview Acadia Healthcare rises as David Einhorn touts the stock
Lilia Valutyte was attacked by Deividas Skebas, 26, in Boston in July 2022 while playing outside her mother’s shop A man who murdered a nine-year-old girl by stabbing her in the heart while she played with a hula hoop in the street has been jailed for life with a minimum term of 25 years. Lilia Valutyte was attacked by Deividas Skebas, 26, in the town centre of Boston, Lincolnshire, on 28 July 202...
Lilia Valutyte was attacked by Deividas Skebas, 26, in Boston in July 2022 while playing outside her mother’s shop A man who murdered a nine-year-old girl by stabbing her in the heart while she played with a hula hoop in the street has been jailed for life with a minimum term of 25 years. Lilia Valutyte was attacked by Deividas Skebas, 26, in the town centre of Boston, Lincolnshire, on 28 July 2022 while she was playing outside her mother’s embroidery shop. Continue reading...